![]() |
|
|
Forward to a colleague |
||
Access Full Stories While India, the Asia-Pacific, Eastern Europe and Latin America are all gaining recognition as potential new hot spots, South Africa remains 'underutilised as a clinical trial destination,' according to a prominent... Read Merck turns to India for latest R&D partnership Merck & Co. has turned to India's Nicholas Piramal (NPIL) for its latest research collaboration, as the preclinical offshoring trend persists... Read Blast at Aesica London plant Contract manufacturer Aesica has confirmed reports of a blast at its Ponders End facility in North London last night, hospitalising three workers... Read CML snaps up API services firm Cambridge Major Laboratories (CML) has bought up a Dutch supplier of active pharmaceutical ingredient (API) development services, creating one of the largest pharma chemistry development organisations in the western... Read Pharmaceutical outsourcing: people on the move AstraZeneca, Encorium, Icon and Eden Biodesign have all had people on the move in the world of pharmaceutical outsourcing... Read |
||||||||||||||
All News Headlines for: November | October | September |
||||||||||||||
Baxter's contract services case study Baxter's contract services case study details the expedited transfer of a commercial launched lyophilized drug to a new production site. Their team designed solutions resulting in cost savings, yield improvement and cycle optimization... Click Here | ||||||||||||||
|
Related Industry News Cystatin C can wash away Alzheimer's plaques Scientists have discovered that a protein called cystatin C can prevent damaging Alzheimer's plaques from forming by keeping their constituent protein water soluble... Read Pipeline match following Celgene's $2.9bn acquisition of Pharmion Celgene has agreed to pay $2.9bn for Pharmion in the hope of becoming a 'global leader in the haematology and oncology field', but do the company's pipelines match up well together?... Read Icahn invests in Genzyme, prompts takeover rumours The man often credited with causing Biogen Idec to be put up for sale, billionaire corporate raider Carl Icahn, has invested in Genzyme and promptly started industry tongues wagging about a takeover... Read Stem cell breakthrough avoids the embryo controversy US researchers have developed a way of creating primate embryonic stem cells that avoids the need to use fertilised embryos, potentially leading to more ethical ways of curing degenerative diseases... Read
|
||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||